Overview

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

Status:
Terminated
Trial end date:
1998-05-04
Target enrollment:
Participant gender:
Summary
Current therapies for Stage IV bladder cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV bladder cancer PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute